LATEST UPDATE ON CIPLA Ltd: Hereunder given report of HSBC on CIPLA:
"HSBC CIPLA GEMs Super 15 – portfolio change Adding Cipla, removing SIPCHEM Adding Cipla (CIPLA IN, Buy, TP: INR795.0, CMP: INR703.2): New product launches in emerging markets along with certain product approvals in the UK and the US should drive earnings in the near term. We expect margins to improve on a y-o-y basis.
Respiratory franchise to double in next 4-5 years with higher growth in the US followed by EU and then EMs Near-term gNexium traction will moderate but will be supported by few exclusive launches in FY17 Gseretide MDI inhaler approval in UK is a near-term catalyst.
We have a Buy rating and fair value target price of INR795"
"HSBC CIPLA GEMs Super 15 – portfolio change Adding Cipla, removing SIPCHEM Adding Cipla (CIPLA IN, Buy, TP: INR795.0, CMP: INR703.2): New product launches in emerging markets along with certain product approvals in the UK and the US should drive earnings in the near term. We expect margins to improve on a y-o-y basis.
Respiratory franchise to double in next 4-5 years with higher growth in the US followed by EU and then EMs Near-term gNexium traction will moderate but will be supported by few exclusive launches in FY17 Gseretide MDI inhaler approval in UK is a near-term catalyst.
We have a Buy rating and fair value target price of INR795"
Dear Sirs
ReplyDeleteThanks for your update it increased our confidence level. Also many other brokerage firm are bullish on CIPLA now. Even one of technical analyst whom I knows has given buy on CIPLA Future. Great pick thanks sirs again